RxDoctor Payments DataLook up a doctor →

Dana Valencia, MD

Cardiovascular Disease · Moberly, MONPI 1902868185

Payments from drug & device makers

$34,046in general payments, 2019–2025

Across 712 payments — averaging $47.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$17K
  • Abbott$6K
  • United Therapeutics Corporation$5K
  • Johnson & Johnson$809
  • Actelion Pharmaceuticals US, Inc.$695
  • Impulse Dynamics (USA) Inc.$612
  • plus $5K from 30 others

What the payments were for

  • Consulting fees$2,8008%
  • Speaking & faculty fees$14,99444%
  • Travel & lodging$2,0236%
  • Food & beverage$14,14442%
  • Education$850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,046 in reported general payments places this provider in the 85th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$162,246
Medicare patients
519
Services billed
2,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat54$622,290
XareltoRivaroxaban266$178,463
EntrestoSacubitril/Valsartan176$129,606
EliquisApixaban96$75,693
FarxigaDapagliflozin Propanediol68$57,523
Orenitram ErTreprostinil Diolamine24$48,944
Repatha SureclickEvolocumab37$27,159
OzempicSemaglutide26$25,291
VerquvoVericiguat24$23,324
JardianceEmpagliflozin27$17,298
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,576
KerendiaFinerenone19$12,723
CorlanorIvabradine Hcl23$12,501
NexletolBempedoic Acid21$11,527
Ranolazine ErRanolazine155$9,400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas, Kerendia$16,764$635,01373 claims
Johnson & JohnsonXarelto$809$178,463266 claims
NovartisEntresto$421$129,606176 claims
PfizerEliquis$86$75,69396 claims
AstraZenecaFarxiga$329$57,52368 claims
Novo NordiskOzempic$17$25,29126 claims
MerckVerquvo$275$23,32424 claims
Boehringer IngelheimJardiance$143$17,29827 claims
AmgenCorlanor$508$12,50123 claims
Esperion Therapeutics, Inc.Nexletol$457$11,52721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Moberly

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →